SCHEMBL1622702

SCHEMBL1622702

CCC(=O)c1c(NC(N)=O)sc(C)c1C

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.68
KMT2A Q03164 3/20 0.55
AIP O00170 1/20 0.53
SGTA O43765 1/20 0.53
TOMM70 O94826 1/20 0.53
STIP1 P31948 1/20 0.53
PPP5C P53041 1/20 0.53
FKBP4 Q02790 1/20 0.53
PPID Q08752 1/20 0.53
FKBP5 Q13451 1/20 0.53
FKBP8 Q14318 1/20 0.53
TOMM34 Q15785 1/20 0.53
DNAJC7 Q99615 1/20 0.53
AIPL1 Q9NZN9 1/20 0.53
STUB1 Q9UNE7 1/20 0.53
ALDH1A1 P00352 10/20 0.49
MAPT P10636 5/20 0.49
HPGD P15428 5/20 0.49
HSD17B10 Q99714 2/20 0.49
APOBEC3G Q9HC16 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25934364 0.76 AIP (0.52) MAPK1KMT2AAIPSGTATOMM70
SCHEMBL1622729 0.73 ALDH1A1 (0.51) MAPK1KMT2AAIPSGTATOMM70
SCHEMBL15185722 0.72 ALDH1A1 (0.62) MAPK1KMT2AALDH1A1MAPTHPGD
SCHEMBL11324603 0.70 AIP (0.66) MAPK1KMT2AAIPSGTATOMM70
SCHEMBL1622930 0.69 MAPK1 (0.78) MAPK1KMT2AALDH1A1MAPTHPGD
SCHEMBL22271631 0.67 ALDH1A1 (0.64) MAPK1KMT2AAIPSGTATOMM70
SCHEMBL7002920 0.66 AIP (0.70) MAPK1KMT2AAIPSGTATOMM70
SCHEMBL17264075 0.66 HPGD (0.36) MAPK1KMT2AALDH1A1MAPTHPGD
SCHEMBL1926572 0.66 MAPT (0.48) MAPK1KMT2AAIPSGTATOMM70
SCHEMBL29505464 0.65 MAPK1 (0.45) MAPK1KMT2AAIPSGTATOMM70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2573559-B1 Modulation of chemosensory receptors and ligands associated therewith SENOMYX INC (US) 2019-03-13 EP disclosed
US-9603848-B2 Modulation of chemosensory receptors and ligands associated therewith SENOMYX, INC. (US) 2017-03-28 US disclosed
EP-2062050-B1 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH SENOMYX INC (US) 2016-05-18 EP disclosed
US-9181276-B2 Modulation of chemosensory receptors and ligands associated therewith SENOMYX, INC. (US) 2015-11-10 US disclosed
US-20140235623-A1 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH SENOMYX, INC. (US) 2014-08-21 US disclosed
US-8633186-B2 Modulation of chemosensory receptors and ligands associated therewith SENOMYX INC. (US) 2014-01-21 US disclosed
US-8541421-B2 Methods of enhancing sweet taste of compositions using substituted thieno{2,3-D}pyrimidines SENOMYX INC. (US) 2013-09-24 US disclosed
EP-2573559-A1 Modulation of chemosensory receptors and ligands associated Senomyx, Inc. (US) 2013-03-27 EP disclosed
EP-2568287-A2 Modulation of chemosensory receptors and ligands associated Senomyx, Inc. (US) 2013-03-13 EP disclosed
US-20110230502-A1 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH SENOMYX, INC. (US) 2011-09-22 US disclosed
US-20110224155-A1 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH SENOMYX INC. (US) 2011-09-15 US disclosed
US-7928111-B2 Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors SENOMYX, INC. (US) 2011-04-19 US disclosed
EP-2062050-A2 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH Senomyx, Inc. (US) 2009-05-27 EP disclosed
WO-2008154221-A2 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH SENOMYX, INC. (US) 2008-12-18 WO disclosed
US-20080306053-A1 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH SENOMYX, INC. (US) 2008-12-11 US disclosed
US-20080306093-A1 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH SENOMYX, INC. (US) 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230502-A1 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH OR51E2, TAS2R50, TAS2R30 MAPK1 3378/4885KMT2A 4389/4885AIP 507/4885
US-20080306093-A1 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH OR51E2, TAS2R50, TAS2R30 MAPK1 3378/4885KMT2A 4389/4885AIP 507/4885
US-20140235623-A1 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH TAS2R30, TAS2R50, TAS2R1 MAPK1 3358/4885KMT2A 4411/4885AIP 281/4885
US-20080306053-A1 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH OR51E2, TAS2R50, TAS2R30 MAPK1 3378/4885KMT2A 4389/4885AIP 507/4885
US-20110224155-A1 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH TAS2R30, TAS2R50, TAS2R1 MAPK1 3358/4885KMT2A 4411/4885AIP 281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.